Veracyte Inc

VCYT · Moat type: UNBESTIMMT

MoatScore

4/10

Fair Value

33 USD

Margin of Safety

-72.1 %

Rating

BEOBACHTEN

Veracyte develops and markets genomic diagnostic tests—primarily in oncology (thyroid, prostate, lung)—that enable physicians to make more precise treatment decisions and are typically billed once per patient.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.